Biogen and Tokyo-based pharmaceutical company Eisai’s Alzheimer’s drug, which recently scored a win in a phase 3 trial by slowing cognitive decline by 27 percent among mild disease patients, has the potential to reverse the course of Alzheimer’s research, The Wall Street Journal reported Sept. 28.
Read the full post on Becker's Hospital Review - Healthcare News
